Compare BridgeBio Pharma Inc (BBIO) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs D Wave Quantum Inc — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while D Wave Quantum Inc trades at $18.3 (market cap $7.02B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× D Wave Quantum Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | QBTS | |
|---|---|---|
Market Cap | $16.46B | $7.02B |
Sector | Health | Technology |
52-Week High | $90.17 | $44.78 |
52-Week Low | $44.81 | $12.98 |
Enterprise Value | $18.02B | $6.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
QBTS trades at $18.67, down 7.05% today amid a broader quantum computing sector sell-off. The stock exhibits a bearish technical signal despite oversold RSI readings, while fundamentals reveal severe losses with a net income margin of -2,957.23% and negative cash flow from operations. Recent news highlights its Nasdaq listing transfer and IDC MarketScape recognition as a quantum computing leader.
Analyst consensus remains strongly bullish with a $39.86 price target, but the stock faces significant execution risks, cash burn, and intense competition. Investment appeal hinges on speculative growth in commercial quantum adoption, yet profitability remains distant, demanding high risk tolerance from investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
